648 related articles for article (PubMed ID: 32923629)
21. SARS-CoV-2 and the safety margins of cell-based biological medicinal products.
Modrof J; Kerschbaum A; Farcet MR; Niemeyer D; Corman VM; Kreil TR
Biologicals; 2020 Nov; 68():122-124. PubMed ID: 32891497
[TBL] [Abstract][Full Text] [Related]
22. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
[TBL] [Abstract][Full Text] [Related]
23. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
24. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
25. p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein.
Panagiotopoulos A; Tseliou M; Karakasiliotis I; Kotzampasi DM; Daskalakis V; Kesesidis N; Notas G; Lionis C; Kampa M; Pirintsos S; Sourvinos G; Castanas E
Pharmacol Res Perspect; 2021 Aug; 9(4):e00798. PubMed ID: 34128351
[TBL] [Abstract][Full Text] [Related]
26. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.
Wan Q; Song D; Li H; He ML
Signal Transduct Target Ther; 2020 Jul; 5(1):125. PubMed ID: 32661235
[TBL] [Abstract][Full Text] [Related]
27. Genome-Wide CRISPR Screen Identifies RACK1 as a Critical Host Factor for Flavivirus Replication.
Shue B; Chiramel AI; Cerikan B; To TH; Frölich S; Pederson SM; Kirby EN; Eyre NS; Bartenschlager RFW; Best SM; Beard MR
J Virol; 2021 Nov; 95(24):e0059621. PubMed ID: 34586867
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
29. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
30. Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules.
Mohan S; Elhassan Taha MM; Makeen HA; Alhazmi HA; Al Bratty M; Sultana S; Ahsan W; Najmi A; Khalid A
Molecules; 2020 Oct; 25(21):. PubMed ID: 33105694
[TBL] [Abstract][Full Text] [Related]
31. Cappariloside A shows antiviral and better anti-inflammatory effects against influenza virus via regulating host IFN signaling, in vitro and vivo.
Li Z; Zhao J; Zhou H; Li L; Ding Y; Li J; Zhou B; Jiang H; Zhong N; Hu W; Yang Z
Life Sci; 2018 May; 200():115-125. PubMed ID: 29555588
[TBL] [Abstract][Full Text] [Related]
32. Reverse engineering synthetic antiviral amyloids.
Michiels E; Roose K; Gallardo R; Khodaparast L; Khodaparast L; van der Kant R; Siemons M; Houben B; Ramakers M; Wilkinson H; Guerreiro P; Louros N; Kaptein SJF; Ibañez LI; Smet A; Baatsen P; Liu S; Vorberg I; Bormans G; Neyts J; Saelens X; Rousseau F; Schymkowitz J
Nat Commun; 2020 Jun; 11(1):2832. PubMed ID: 32504029
[TBL] [Abstract][Full Text] [Related]
33. Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.
Milewska A; Kula-Pacurar A; Wadas J; Suder A; Szczepanski A; Dabrowska A; Owczarek K; Marcello A; Ochman M; Stacel T; Rajfur Z; Sanak M; Labaj P; Branicki W; Pyrc K
J Virol; 2020 Jul; 94(15):. PubMed ID: 32434888
[TBL] [Abstract][Full Text] [Related]
34. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR; Dhamdhere G; Liu Y; Lin X; Goudy L; Zeng L; Chemparathy A; Chmura S; Heaton NS; Debs R; Pande T; Endy D; La Russa MF; Lewis DB; Qi LS
Cell; 2020 May; 181(4):865-876.e12. PubMed ID: 32353252
[TBL] [Abstract][Full Text] [Related]
35. Potential Antiviral Options against SARS-CoV-2 Infection.
Ianevski A; Yao R; Fenstad MH; Biza S; Zusinaite E; Reisberg T; Lysvand H; Løseth K; Landsem VM; Malmring JF; Oksenych V; Erlandsen SE; Aas PA; Hagen L; Pettersen CH; Tenson T; Afset JE; Nordbø SA; Bjørås M; Kainov DE
Viruses; 2020 Jun; 12(6):. PubMed ID: 32545799
[TBL] [Abstract][Full Text] [Related]
36. Loss of the Nuclear Protein RTF2 Enhances Influenza Virus Replication.
Chia BS; Li B; Cui A; Eisenhaure T; Raychowdhury R; Lieb D; Hacohen N
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878895
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
Deng W; Xu Y; Kong Q; Xue J; Yu P; Liu J; Lv Q; Li F; Wei Q; Bao L
Signal Transduct Target Ther; 2020 May; 5(1):66. PubMed ID: 32385228
[No Abstract] [Full Text] [Related]
38. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.
Su HX; Yao S; Zhao WF; Li MJ; Liu J; Shang WJ; Xie H; Ke CQ; Hu HC; Gao MN; Yu KQ; Liu H; Shen JS; Tang W; Zhang LK; Xiao GF; Ni L; Wang DW; Zuo JP; Jiang HL; Bai F; Wu Y; Ye Y; Xu YC
Acta Pharmacol Sin; 2020 Sep; 41(9):1167-1177. PubMed ID: 32737471
[TBL] [Abstract][Full Text] [Related]
39. A diarylamine derived from anthranilic acid inhibits ZIKV replication.
Silva S; Shimizu JF; Oliveira DM; Assis LR; Bittar C; Mottin M; Sousa BKP; Mesquita NCMR; Regasini LO; Rahal P; Oliva G; Perryman AL; Ekins S; Andrade CH; Goulart LR; Sabino-Silva R; Merits A; Harris M; Jardim ACG
Sci Rep; 2019 Nov; 9(1):17703. PubMed ID: 31776405
[TBL] [Abstract][Full Text] [Related]
40. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
